PMID- 32989751
OWN - NLM
STAT- MEDLINE
DCOM- 20210617
LR  - 20210617
IS  - 1365-4632 (Electronic)
IS  - 0011-9059 (Linking)
VI  - 60
IP  - 2
DP  - 2021 Feb
TI  - Dupilumab treatment ameliorates clinical and hematological symptoms, including 
      blood eosinophilia, in patients with atopic dermatitis.
PG  - 190-195
LID - 10.1111/ijd.15183 [doi]
AB  - BACKGROUND: Atopic dermatitis (AD) is an allergic disease that affects 
      individuals of various ages. Recently, the IL-4/13 inhibitor dupilumab has gained 
      regulatory approval for clinical use in AD patients. Dupilumab has been reported 
      to reduce several markers of AD, including the serum levels of thymus and 
      activation-regulated chemokine (TARC/CCL17), blood lactate dehydrogenase (LDH), 
      and serum total immunoglobulin E (IgE). METHODS: We retrospectively reviewed data 
      from 40 AD patients who were treated with dupilumab. Eczema Area and Severity 
      Index (EASI), Investigator's Global Assessment (IGA), body surface area (BSA) 
      scores, TARC, LDH, total IgE, and eosinophil count in peripheral blood were 
      assessed for a total of 32 weeks. RESULTS: The EASI, IGA, and BSA scores improved 
      significantly with treatment, indicating a reduction in AD severity. Serum TARC 
      and LDH levels also significantly decreased with treatment. Serum IgE levels were 
      unchanged at 2 weeks of treatment but decreased significantly between 4 and 
      32 weeks. The number of eosinophils in the peripheral blood decreased at 4, 16, 
      and 32 weeks after treatment initiation. CONCLUSIONS: Several studies have 
      reported that serum TARC, LDH, and total IgE levels are reduced by dupilumab 
      treatment. Our real-world data are the first to demonstrate a reduction in blood 
      eosinophilia in patients who receive clinical treatment with dupilumab.
CI  - (c) 2020 the International Society of Dermatology.
FAU - Yamauchi, Teruo
AU  - Yamauchi T
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Sasaki, Shun
AU  - Sasaki S
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Lee, Eun Seon
AU  - Lee ES
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Tamura, Takayuki
AU  - Tamura T
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Seki, Marina
AU  - Seki M
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Miwa, Tasuku
AU  - Miwa T
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Kobayashi, Kae
AU  - Kobayashi K
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Saruta, Yusuke
AU  - Saruta Y
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Kitami, Yuki
AU  - Kitami Y
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Sueki, Hirohiko
AU  - Sueki H
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
FAU - Watanabe, Hideaki
AU  - Watanabe H
AUID- ORCID: 0000-0002-9367-5167
AD  - Department of Dermatology, Showa University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200929
PL  - England
TA  - Int J Dermatol
JT  - International journal of dermatology
JID - 0243704
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - *Dermatitis, Atopic/drug therapy
MH  - *Eczema
MH  - *Eosinophilia/drug therapy
MH  - Humans
MH  - Retrospective Studies
MH  - Severity of Illness Index
EDAT- 2020/09/30 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/09/29 05:39
PHST- 2020/05/27 00:00 [received]
PHST- 2020/08/04 00:00 [revised]
PHST- 2020/08/26 00:00 [accepted]
PHST- 2020/09/30 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/09/29 05:39 [entrez]
AID - 10.1111/ijd.15183 [doi]
PST - ppublish
SO  - Int J Dermatol. 2021 Feb;60(2):190-195. doi: 10.1111/ijd.15183. Epub 2020 Sep 29.